ARCHIVES

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Wyngaarden Recommendation On New Director Due Nov. 1o; Five Staff Members Nominated

November 4, 1988

Proteomics Promises Ways To Track Response To Therapy

April 25, 2003

After 30 Years As NCI-Designated Center, Vermont Cancer Center Loses Core Grant.

November 14, 2008

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

FDA Committee Approves Two NDAs, Blocks One, Hears NCI Toxicology Plan

June 15, 1979

Salmon Enthusiastic About Comprehensive Core Grant Plan

May 6, 1988